The predicted effect of changes in cervical screening practice in the UK: results from a modelling study by Canfell, K et al.
The predicted effect of changes in cervical screening practice in
the UK: results from a modelling study
K Canfell
1, R Barnabas*,1, J Patnick
2 and V Beral
1
1Cancer Research UK Epidemiology Unit, University of Oxford, Gibson Building, Radcliffe Infirmary, OX2 6HE, UK;
2Director, NHS Cancer Screening
Programmes, The Manor House, 260 Ecclesall Road South, Sheffield, S11 9PS, UK
In 2003, the National Health Service Cervical Screening Programme (NHSCSP) announced that its screening interval would be
reduced to 3 years in women aged 25–49 and fixed at 5 years in those aged 50–64, and that women under 25 years will no longer
be invited for screening. In order to assess these and possible further changes to cervical screening practice in the UK, we constructed
a mathematical model of cervical HPV infection, cervical intraepithelial neoplasia and invasive cervical cancer, and of UK age-specific
screening coverage rates, screening intervals and treatment efficacy. The predicted cumulative lifetime incidence of invasive cervical
cancer in the UK is 1.70% in the absence of screening and 0.77% with pre-2003 screening practice. A reduction in lifetime incidence
to 0.63% is predicted following the implementation of the 2003 NHSCSP recommendations, which represents a 63% reduction
compared to incidence rates in the UK population if it were unscreened. The model suggests that, after the implementation of the
2003 recommendations, increasing the sensitivity of the screening test regime from its current average value of 56 to 90% would
further reduce the cumulative lifetime incidence of invasive cervical cancer to 0.46%. Alternatively, extending screening to women
aged 65–79 years would further reduce the lifetime incidence to 0.56%. Screening women aged 20–25 years would have minimal
impact, with the cumulative lifetime incidence decreasing from 0.63 to 0.61%. In conclusion, the study supports the 2003
recommendations for changes to cervical screening intervals.
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The implementation of the National Health Service Cervical
Screening Programme (NHSCSP) in 1988 resulted in a substantial
reduction in the overall incidence of cervical cancer (Quinn et al,
1999). The NHSCSP has invited women aged 20–64 years for
cervical cancer screening every 3–5 years, depending upon the
specific policy of the local Health Authority. In 2003, the NHS
announced that women aged 25–49 years will be invited for
screening every 3 years, while those aged 50–64 should be invited
every 5 years. It was also recommended that women under 25 years
should no longer be screened. The new screening interval
recommendations are based on the estimated duration of the
protective effect of screening in different age groups and are the
result of an audit of the screening histories of women with frankly
invasive cancer and age-matched controls (Sasieni et al, 2003).
In order to investigate the likely impact of changes in screening
practice upon the incidence of invasive cervical cancer in the UK,
we developed a mathematical model of cervical human papillo-
mavirus (HPV) infection, cervical intraepithelial neoplasia (CIN)
and invasive cervical cancer, and of screening in the UK
population. The model was developed so that parameters such as
the frequency of screening within various age groups and
sensitivity of the screening test could be altered in a systematic
way. We then evaluated the impact of the 2003 recommendations
on cervical cancer incidence rates in the UK and also explored the
impact of possible further changes in screening practice.
MATERIALS AND METHODS
Model description
A Markov simulation was developed with two components. The
first component involved the development of a mathematical
model of HPV natural history, progression to CIN and cervical
cancer within the UK population. The second model component
dealt with the screening and treatment of preneoplastic disease.
The health states in the final model are illustrated in Figure 1. The
simulation follows a cohort of women, year by year, from age 16 to
80 years. The model assumes that the women are always in one of
nine possible states, with transitions between states occurring
annually according to age-dependent probabilities.
Natural history model component
The simulation commences with a cohort of 100000 16-year-old
girls and it is assumed that the majority (approximately 89%) of
these are HPV naı ¨ve, approximately 10% have asymptomatic
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ycervical HPV infection and 1% have CIN 1. Each year, an age-
specific risk of acquiring an HPV infection is applied to women in
the cohort. The state of ‘cervical HPV infection’ in Figure 1
represents the presence of PCR-detectable HPV DNA without the
development of CIN. The next four states in Figure 1 represent
further stages of disease pathogenesis – CIN 1, CIN 2, CIN 3 and
invasive cervical cancer, which includes both microinvasive (Stage
1A) and frankly invasive (Stages 1Bþ) cancer. Women may die
from cervical cancer (death from cervical cancer) and women in
each of the other states are subject to age-specific mortality from
other causes (death from other cause). Age-specific death rates for
causes other than cervical cancer were obtained using overall
mortality rates for England and Wales and subtracting the
mortality rates for cervical cancer (Office of National Statistics,
2003a). At each stage of infection, HPV infection or CIN lesions
can regress, persist or progress.
The parameters used for HPV and CIN regression and
progression were based on a systematic review of the relevant
literature in order to determine age-specific transition rates at each
stage. The progression and regression rates were converted to
annual transition probabilities using the method of Miller and
Homan (1994), and these are given in Table 1. As young women
more commonly have transient infections than older women
(Hildesheim et al, 1994), age-dependent transition rates from
asymptomatic HPV infection to CIN and age-dependent transi-
tions between the various grades of CIN were incorporated into the
model.
Screening and treatment model component
We chose model parameters to simulate screening and treatment
according to national guidelines for the NHSCSP and with the
reported efficacy of the NHSCSP (Department of Health, 2001). In
accordance with pre-2003 UK practice, women aged between 20
and 64 years have been invited for cytological smear screening,
with follow-up, referral for evaluation and/or treatment being
dependent upon the screening result. The model incorporates the
reported age-specific distribution of 5-year screening coverage
rates in England, with over 80% of women between 25 and 64 years
screened every 5 years (see Table 2).
The assumed sensitivity of the Papanicolaou smear for CIN 2/3
and cancer lesions in the baseline model was derived from a meta-
analysis (Nanda et al, 2000). An adjustment was applied in order to
account for the slightly higher effective cytology threshold
required for colposcopy referral in the UK, since women with a
single equivocal (borderline changes) or low-grade (mild dyskar-
yosis) smear result are not automatically referred. We assumed
that the imminent transition to liquid-based cytology in the UK
will significantly reduce the rate of unsatisfactory smears, but will
have a limited effect on the sensitivity of detection of high-grade
disease (National Institute for Clinical Excellence, 2003). There-
fore, our baseline model is equally valid for conventional
cytological screening or in the context of the imminent introduc-
tion of liquid-based cytology to the screening programme in the
UK. The sensitivity of screening can be varied in the model as
appropriate, to reflect the sensitivity of technologies such as HPV
DNA testing, or adjunctive test combinations.
We assumed that all unsatisfactory smears were repeated and
that follow-up of borderline and mild dyskaryosis smears and any
subsequent referrals to colposcopy were completed within 1 year.
In accordance with current UK practice, we assumed that
confirmed CIN 1 lesions are monitored colposcopically rather
than immediately treated. Once referred to colposcopy, we
assumed that 90% of women with a CIN 2, CIN 3 or invasive
cancer received appropriate follow-up and treatment within the
year that they were referred. The remaining 10% of women were
assumed to remain untreated due either to colposcopic misclassi-
fication of disease or patient noncompliance. For treated women,
we assumed eradication of cervical HPV infection in 73% of cases
(Bodner et al, 2002) and in the remaining 27% we assumed
eradication of the CIN lesion, but persistence of cervical HPV
infection.
Model outputs
The model output was the annual age-specific incidence of
invasive cervical cancer. This provides a prediction of the number
of women with cervical cancer at each age, per 100000 women of
the same age, by single years of age from 16 to 79. We then
calculated several summary measures of the predicted incidence,
Uninfected
Cervical HPV 
infection 
CIN 1 
CIN 2 
Invasive 
cervical  
cancer   Death from cervical
cancer 
Death from
other cause 
Treatment following 
positive screening result 
and diagnostic
confirmation 
CIN 3 
Death from
other cause
Figure 1 Markov model incorporating states for cervical HPV infection, CIN and treatment of screen-detected disease.
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yas follows: (1) the age-specific incidence averaged across 5-year
age bands and presented graphically, which allows direct
comparison with age-specific incidence rates in England; (2) the
cumulative lifetime incidence of invasive cervical cancer, from age
20 to 80 years, expressed as a percentage; and (3) the age-
standardised incidence rate, standardised to the European
standard population (Esteve et al, 1994). To permit direct
comparisons of the model predictions of incidence rates with
England cancer registration rates, we did not account for women
who had a hysterectomy for reasons unrelated to cervical
neoplastic disease. Not adjusting for hysterectomy allows direct
comparison with national cervical cancer incidence rates (Redburn
and Murphy, 2001), but does not affect the comparison between
the outcomes arising from various interventions.
Table 1 Annual transition probabilities for the natural history model
Parameter Annual transition probability References
Uninfected to Cervical HPV infection (HPV incidence) Age
16–19 0.0855 Barnabas and Garnett, 2004; Schiffman and Kjaer, 2003; Melkert
et al, 1993 20–24 0.2500
25–29 0.1500
30–34 0.0576
35–39 0.0333
40–44 0.0333
45–49 0.0333
50+ 0.0222
Cervical HPV infection to Uninfected Age
16–29 0.7000 Myers et al, 2000; Hildesheim et al, 1994; Moscicki et al, 1998;
Koutsky et al, 1992; Ho et al, 1998; Molano et al, 2003 30+ 0.4130
Cervical HPV infection to CIN 1 or CIN 2 0.0959 Myers et al, 2000; Moscicki et al, 1998
Proportion of Cervical HPV infection progressing directly to
CIN 2
0.1350 Myers et al, 2000; Schlecht et al, 2001
CIN 1 to Cervical HPV infection or Uninfected Age
16–34 0.2248 Myers et al, 2000; Yokoyama et al, 2003; Syrjanen et al, 1992;
de Brux et al, 1983 35+ 0.1124
Proportion CIN 1 regressing directly to Uninfected 0.90 Syrjanen et al, 1992
CIN 1 to CIN 2 Age
16–34 0.0297 de Brux et al, 1983; Syrjanen et al, 1992; Myers et al, 2000
35+ 0.1485
CIN 1 to CIN 3 0.0301 Yokoyama et al, 2003
CIN 2 to Cervical HPV infection or Uninfected 0.1901 Yokoyama et al, 2003
Proportion CIN 2 regressing directly to Uninfected 0.90 Syrjanen et al, 1992
CIN 2 to CIN 1 0.2430 Syrjanen et al, 1992
CIN2 to CIN 3 Age
16–34 0.0389 Syrjanen et al, 1992; de Brux et al, 1983; Yokoyama et al, 2003
35–44 0.0797
45+ 0.1062
CIN 3 to Cervical HPV infection or Uninfected Age
16–44 0.0135 Syrjanen et al, 1992
45+ 0.0100
Proportion CIN 3 regressing directly to Uninfected 0.50 Syrjanen et al, 1992
CIN 3 to CIN 1 0 —
CIN 3 to CIN 2 0.0135 —
CIN 3 to Invasive cervical cancer 0.0099 Syrjanen et al, 1992; Ostor, 1993; McIndoe et al, 1984
Invasive cervical cancer to Death from invasive cervical cancer 0.025 —
Transitions to Death from other cause Age
16–24 0.0003 Office of National Statistics, 2003a
25–34 0.0004
35–44 0.0010
45–54 0.0026
55–64 0.0066
65–74 0.0192
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Sensitivity analysis was used to assess the effect of varying
individual model parameters during the construction and testing
of the model. Following validation of the baseline model output
against observed cancer incidence rates in the UK, scenario
analysis was used to explore the impact of changes to the screening
test sensitivity, the age of women invited for screening and the
screening interval in different age groups.
Software
Markov cohort analysis was performed using DATA 4.0.7 Software
(TreeAge Software, Williamstown, MA, USA). Post-processing of
the data was performed using STATA 7.0 (Stata Corp, College
Station, TX, USA).
RESULTS
HPV prevalence
The model prediction of the age-specific prevalence of HPV
infection in women without CIN is given in Figure 2. The model
was calibrated against two sources of data for cross-sectional age-
specific prevalence of HPV DNA positivity, based on PCR testing.
A survey in the Netherlands (Melkert et al, 1993) assessed cross-
sectional prevalence of all HPV types in approximately 1700
cytologically normal women. The Portland Kaiser survey in the
USA involved an assessment of the prevalence of oncogenic HPV
types in more than 20000 women (Schiffman and Kjaer, 2003).
Survey data on HPV prevalence in women aged over 65 years were
not available for comparison with the model results. At ages 20–
64, satisfactory agreement between the model-predicted and
observed prevalence is observed, with a peak HPV prevalence of
20–25% at age 20–24 years, declining thereafter to less than 10%
in women over 35 years of age.
Invasive cancer incidence
The predicted age-specific annual incidence of invasive cervical
cancer in the UK population in the absence of screening is given in
Figure 3. Assuming no screening, the model predicts a cumulative
lifetime incidence of cervical cancer of 1.70% and an age-
standardised incidence of 18.6 per 100000 annually. The predicted
cancer incidence increases with age until about 55 years and then
remains relatively flat, which is in keeping with observed trends in
unscreened populations (Beral et al, 1994). Figure 3 also shows the
predicted effect of the pre-2003 UK screening programme on the
incidence of invasive cancer, which agrees closely with England
cancer registration data for annual cervical cancer incidence rates
(Office of National Statistics, 2001, 2003b). Average age-specific
cervical cancer incidence rates for the years 1998–2000 are shown,
with bars indicating the range of values observed over the 3 years.
The predicted age-specific incidence curve is within the observed
3-year range at most ages, with the possible exception of ages 40–
44, where the model predicts slightly lower than observed
incidence rates. Overall, the model predicts a reduction in the
cumulative lifetime incidence to 0.77% with pre-2003 screening
Table 2 Parameters for screening and treatment model
Screening parameters
Baseline parameter
value Scenario analysis range Reference for baseline parameter value
Screening coverage Age Coverage Extend screening to women aged
65–79 years
Department of Health, 2001
25–29 77.0%
30–34 83.0%
35–39 85.0% Increase coverage to 77% in
women aged 20–24 40–44 85.5%
45–49 86.0%
50–55 85.0%
55–59 82.5%
60–64 77.5%
(average rate 83% over 5
years)
Screening interval 3–5 years 2003 recommendations: no
screening ages 20–24; 3 years
ages 25–49; 5 years ages 50–64
Department of Health, 2001; Sasieni et al, 2003
Pap sensitivity 55.6% 40–90% Nanda et al, 2000
Proportion HPV-positive post treatment 27% — Bodner et al, 2002
Treatment success (failure due to noncompliance
or misdiagnosis)
90% — —
0
0.05
0.1
0.15
0.2
0.25
0.3
20−24
25−29
30−34
35−39
40−44
45−49
50−54
55−59
60−64
65−69
70−74
75−79
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Figure 2 Prevalence of cervical HPV infection (PCR detectable HPV
DNA) found in population surveys in the Netherlands and the USA,
compared to the model prediction.
aMelkert et al (1993);
bSchiffman and
Kjaer (2003).
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0.73% based on 1998–2000 UK age-specific incidence rates (Office
of National Statistics, 2001, 2003b). The model-predicted age-
standardised incidence is 8.7 per 100000 women per year, which is
also close to the average cancer registration rate of 9.0 per 100000
observed from 1998–2000 in the UK (Office of National Statistics,
2001, 2003b). The cancer registration data show an increase in age-
specific incidence rates for women aged over the age of 65 years,
following the cessation of screening, and this pattern is also
observed in the model results.
Effect of changes to screening practice
Figure 4 shows the predicted effect of implementing the 2003
NHSCSP recommended changes in screening intervals, assuming
that current levels of population coverage are maintained with
more frequent screening in younger women. The age-specific
cancer incidence curve demonstrates that the additional benefits of
3-yearly screening in women aged under 50 years would still be
evident when these women reached the age 50–69 years, due to
increased early detection and treatment of precancerous lesions.
The model predicts that the changes in screening intervals will
further reduce the cumulative lifetime incidence of cervical cancer
by 18% compared to pre-2003 screening, from 0.77 to 0.63%.
Compared to no screening at all in the UK population, which
corresponds to an estimated lifetime incidence of 1.70% (Figure 3),
the overall proportion of cancers prevented in women aged 20–79
years after implementing the 2003 NHSCSP recommendations is
estimated to be 63%, with a predicted age-standardised incidence
of 6.9 per 100000 women.
Figure 5 shows the effect of incorporating the 2003 screening
interval recommendations and then varying the sensitivity of the
screening test (or combination of tests) between 40 and 90%,
assuming that the average sensitivity of the cytological smear is
56% (Nanda et al, 2000). Increasing the screening sensitivity to
70% would result in an estimated further reduction of cumulative
lifetime incidence of 14% from 0.63 to 0.54%, and increasing the
sensitivity to 90% or higher would result in a further lifetime
incidence reduction of 27%, to 0.46%. Such improvements in
screening sensitivity could potentially be achieved, for example,
with primary HPV DNA testing (Cuzick et al, 2003). In contrast, a
22% increase in the lifetime incidence of cervical cancer (to 0.77%)
is predicted if the screening test sensitivity is decreased to 40%.
Figure 6 shows the effect of incorporating the 2003 screening
interval recommendations and then varying the age of women
invited for screening. Increasing the population coverage age range
by extending screening to women aged 65–79 years would result in
a predicted further decrease of 11% in cumulative lifetime
incidence, from 0.63 to 0.56%. However, continuing to system-
atically invite women in the 20–24 year age group once in the 5-
year period would result in a minimal 3% decrease in the lifetime
incidence of cervical cancer to 0.61%, even if coverage rates of over
75% were achieved in this age group.
DISCUSSION
Although the molecular events involved in cervical HPV infection
and the development of neoplasia are not completely understood,
the clinical course of cervical carcinogenesis is now relatively well
charted. Therefore, the natural history of cervical disease lends
itself to a modelling approach. Modelling can assist with decision
making by exploring the implications of a range of possible
interventions (Royston, 1999) and has been previously used to
evaluate the natural history of CIN (Myers et al, 2000) and changes
in screening practice (Sherlaw-Johnson et al, 1994, 1999). The
model we have described builds on previous work to provide a tool
that encompasses the current understanding of the natural history
of cervical neoplasia and is specific to the UK setting.
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Figure 3 Observed and predicted incidence of invasive cervical cancer in
the UK.
aCancer Registrations in England, 1998–2000. Office of National
Statistics.
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aCancer Registrations in England, 1998–2000. Office of
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Figure 5 Effect of varying the sensitivity of cervical screening, after
implementing the 2003 screening interval changes.
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cancer and the screening and treatment of cervical disease to
predict cancer incidence rates in the UK population under various
conditions. The predicted age-specific cervical cancer incidence in
the absence of screening was 18.6 per 100000 women, standardised
to the European standard population. The cancer registration data,
standardised to the same population, suggest rates between 14 and
16 per 100000 during the 1970s and 1980s in England (Quinn et al,
1999). Some opportunistic cervical screening was performed in the
UK from the 1960s and, as expected, the observed incidence in the
context of opportunistic screening was slightly less than the model
prediction for a completely unscreened population. Since cancer
registration data for England, which has only been collected since
the early 1970s, incorporates a screening effect, they cannot be
used to validate the model prediction for the incidence of cervical
cancer in the UK population in the absence of screening. There are
additional problems associated with using historical data, in terms
of disentangling the influence of cohort effects related to
differential HPV exposure and the influence of changing practice
in screening, diagnostic and treatment procedures. For these
reasons, we thought it most appropriate to estimate the validity of
the model by incorporating the effect of pre-2003 screening
practice and comparing the model predictions of cervical cancer
incidence rates with recent cancer registration data for the UK. We
found close agreement between the observed and predicted values
of age-specific cervical cancer incidence, cumulative lifetime
incidence and age-standardised incidence in the screened UK
population (Figure 3).
The primary objective of the study was to assess the likely long-
term impact of the 2003 NHSCSP recommended changes in
screening intervals. Although the current study has focused upon
screening in the UK, a Working Group of the International Agency
for Research on Cancer (IARC) has recently confirmed the efficacy
of screening every 3 years between the ages of 25 and 49 years and
every 5 years between the ages of 50 and 64 years (International
Agency for Research on Cancer, 2004), and therefore our results
also have more general implications. We found that ceasing
screening in women under the age of 25 years will have a very
small effect on the lifetime incidence of cervical cancer. Reducing
the screening interval to 3 years in women aged 25–49 will have
major benefits, resulting in an 18% reduction of the cumulative
lifetime incidence of cervical cancer, compared to pre-2003
screening. As a result, the predicted proportion of cervical cancers
prevented in women aged 20–79, compared to an unscreened
population, is 63%. Our findings of a reduction in cervical cancer
incidence broadly agree with the original estimates performed by
Sasieni et al (2003), who found that the new screening intervals
would be associated with a 61% reduction in women aged 20–39
years and an 84% reduction in women aged 40–54 years,
compared to women who were never screened. However, the
results are not directly comparable because our model included
microinvasive cancers, whereas their estimate was based on 1305
women aged 20–69 years with Stage 1Bþ cancer and 2532 age-
matched control women, but did not include 537 microinvasive
(Stage 1A) cancers and 490 cancers of unknown stage observed in
women of the same age group. Also, Sasieni et al assumed that all
women with abnormal smears are prevented from developing
cancer, which is not assumed in our model. They calculated the
relative risks resulting from 3- or 5-year screening intervals in
various age groups as a function of the time since the last negative
smear, and then derived a summary measure of the overall
proportion of cancers preventable, using a previously described
method (Sasieni et al, 1996). This approach provided a measure of
the efficacy of screening in individuals who complied with
screening recommendations. Our study extends these results by
assessing the overall effectiveness of the proposed NHSCSP
changes across the lifetime of a cohort of women, taking into
account real-world limitations in population screening coverage
rates, the sensitivity of screening and the efficacy of treatment. For
women over 50 years of age, the modelling approach takes into
account the carried-over beneficial effect resulting from previous
3-yearly screening of the cohort when they were aged 25–49 years,
whereas this carry-over effect could not be taken into account in
the relative risk estimates performed by Sasieni et al.
Some further reductions in cervical cancer incidence could be
achieved after the implementation of the 2003 screening interval
recommendations, by means of increasing the sensitivity of the
screening test or extending screening to older women. Increasing
the sensitivity of the screening test would result in a substantial
further reduction of the cumulative lifetime incidence of cervical
cancer, of up to 27%. Alternatively, when we examined the
possibility of extending screening to include 5-yearly coverage of
women aged 65–79 years, we found that there was an 11% further
reduction in cumulative lifetime incidence predicted. However,
this measure does not take into account the person-years saved,
and reducing incidence in women over 65 years of age is expected
to save fewer years of life compared to reducing incidence in
younger women. Therefore, when comparing the two possible
strategies, both the relative magnitudes of the expected improve-
ments and the age ranges over which incidence is reduced would
suggest that increasing screening sensitivity would be the most
preferable option for the future. However, cost-effectiveness
analysis is required to fully assess the public health impact of
such future screening strategies.
In conclusion, a UK-specific Markov model for cervical HPV
infection, CIN and invasive cervical cancer has been constructed,
successfully validated against cancer registration data and used as
a tool to evaluate the impact of screening policy changes. The
results support the 2003 NHSCSP recommendations that screening
should start at age 25 years, that screening intervals should be
reduced to 3 years in women aged 25–49 years and that screening
intervals should be standardised to 5 years in those aged 50–64,
and suggest that a substantial further reduction in cervical cancer
incidence should follow.
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